It could limit multidrug resistance by targeting and disrupting key elements in bacterial cells. The new drug is the result of an collaborative research which was led by the Institute for Glycomics, Griffith University, in collaboration with scientists from Queensland University of Technology, Indiana University (USA) and Dezhou University (China). Professor Zhou said the new type of antibiotic worked by destroying the structure of essential protein to disable its function.
“Our technique with this new antibiotic approach is different; instead of binding to the surface of the protein, we disrupt the structure of the protein, which stops it functioning,” Professor Yaoqi Zhou from Griffith’s Institute for Glycomics said. He also explained this new approach is less susceptible to antibiotic resistance. This new antibiotic is very specific and will protect the normal intestinal flora unaffected. There is another important hope: “We can theoretically use the same technique to target cancer-causing proteins and viral proteins, so this will be a unique way to approach drug resistance in cancer patients. We’ve done an initial study on cancer cells and we do find it’s able to inhibit the growth of cancer cells. But there’s still a lot of work to do” researchers said.